Centro Privado de RMI Río Cuarto

Centro Privado de RMI Río Cuarto
CGI, Pedernera 459, X5800CGI Río Cuarto, Córdoba, Argentina
Select an option

Our team

Medical staff
Alejo Lingua

Open studies

Breast Cancer
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer - OVELIA - Tolmar Inc.See more
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) - IZABRIGHT-Breast01 - SystImmune Inc.See more
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) - HERTHENA-Breast04 - Merck Sharp & Dohme LLCSee more
Lung cancer
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - MK 2870-007 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) - MK-2870-009 - Merck Sharp & Dohme LLCSee more
Head and neck cancer
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone - Boehringer IngelheimSee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy